DRUG (Bright Minds Biosciences) Moat Score: 2/10 (As of Jun. 28, 2026)


DRUG Bright Minds Biosciences Inc DRUG
34 GF Score
Price $65.79
! 2 Warning Signs
View Full Analysis

What is Bright Minds Biosciences Moat Score?

Bright Minds Biosciences DRUG +3.35% 34 Moat Score is 2 as of Jun. 28, 2026. GuruFocus rates DRUG with a GF Score™ of 34/100. The stock has 2 warning signs investors should review. Among 1,402 Biotechnology companies, Bright Minds Biosciences ranks better than 58.06% on this metric.

Bright Minds Biosciences has the Moat Score of 2, which implies that the company might have No Moat - Very weak/transient advantages.

Bright Minds Biosciences has No Moat: Bright Minds Biosciences Inc lacks significant market leadership and customer loyalty. The company does not possess strong intellectual property or cost advantages, and there are no significant regulatory barriers or network effects. Its competitive position is weak.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes Bright Minds Biosciences might have No Moat - Very weak/transient advantages.

Bright Minds Biosciences  (NAS:DRUG) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

Bright Minds Biosciences Moat Score Related Terms

DRUG vs VRTX, REGN, ALNY: Moat Score Comparison

For the Biotechnology subindustry, Bright Minds Biosciences's Moat Score, along with its competitors' market caps and Moat Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Bright Minds Biosciences Moat Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Bright Minds Biosciences's Moat Score distribution charts can be found below:

* The bar in red indicates where Bright Minds Biosciences's Moat Score falls into.


DRUG
34GF Score
Bright Minds Biosciences Inc DRUG
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Moat Score →
What does a Moat Score of 2 mean?
Bright Minds Biosciences (DRUG) has a Moat Score of 2 as of Jun. 28, 2026. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. According to the industry distribution chart, Bright Minds Biosciences ranks #588 out of 1402 companies in the Biotechnology industry, placing it in the top 41.9%.
Is Bright Minds Biosciences' Moat Score too high?
Bright Minds Biosciences' current Moat Score is 2. The Biotechnology industry median Moat Score is 2.00. Bright Minds Biosciences' value of 2 is 0% at this industry median. Based on the distribution chart, Bright Minds Biosciences ranks #588 out of 1402 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Bright Minds Biosciences has a GF Score™ of 34/100, reflecting its overall financial health beyond just this single metric.
How does Bright Minds Biosciences' Moat Score compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Bright Minds Biosciences ranks #588 out of 1402 companies for Moat Score. This puts Bright Minds Biosciences in the upper half of its industry. The industry median Moat Score is 2.00. Bright Minds Biosciences' value of 2 is 0% at this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Moat Score for a Biotechnology company?
The median Moat Score among Biotechnology companies is 2.00, based on 1,402 companies in the industry. Companies in the top quartile (top 25%) have a Moat Score significantly above this median, while those in the bottom quartile fall well below. However, Moat Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Bright Minds Biosciences's current Moat Score of 2 is 0% at the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Moat Score mean?
A high Moat Score can signal that a stock is expensive relative to its fundamentals. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. For the Biotechnology industry, the median Moat Score is 2.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Bright Minds Biosciences's current Moat Score is 2. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bright Minds Biosciences stock overvalued right now?
Bright Minds Biosciences (DRUG) has a current Moat Score of 2. The current Moat Score is 2 and 0% at the Biotechnology industry median of 2.00. Bright Minds Biosciences' overall GF Score™ is 34/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Moat Score calculated?
Moat Score is calculated from a company's financial statements. For Bright Minds Biosciences (DRUG), the current Moat Score is 2 as of Jun. 28, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Bright Minds Biosciences Business Description

Other Exchanges DRUG:Canada
Address 19 Vestry Street, New York, NY, USA, 10013
Bright Minds Biosciences Inc is focused on developing novel, transformative treatments for neuropsychiatric disorders, epilepsy, and pain. The company has a portfolio of next-generation serotonin agonists designed to target neurocircuit abnormalities that are responsible for difficult-to-treat disorders such as resistant epilepsy, treatment-resistant depression, PTSD, and pain. The company's drugs have been designed to potentially retain the powerful therapeutic aspects of psychedelic and other serotonergic compounds, while minimizing the side effects, thereby creating superior drugs to first-generation compounds, such as psilocybin.
34GF Score

Get the complete analysis for DRUG

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$65.79
Price